02044nas a2200337   4500000000100000008004100001260001300042653001000055653002000065653001800085653002000103653001100123653002100134653001200155653000900167653001600176653001400192653002400206653001500230653001600245100001400261700001500275700001500290700001700305245013200322856004100454300000900495490000700504520118100511022001401692       1991                            d  c1991 Mar10aAdult10aCells, Cultured10aDexamethasone10aGlucocorticoids10aHumans10aInterferon-gamma10aleprosy10aMale10aMiddle Aged10aMonocytes10aOxidation-Reduction10aPrednisone10aSuperoxides1 aVachula M1 aHolzer T J1 aNelson K E1 aAndersen B R00aEffect of glucocorticoids and interferon-gamma on the oxidative responses of monocytes from leprosy patients and normal donors.  uhttp://ila.ilsl.br/pdfs/v59n2a07.pdf  a41-80 v593 a<p>Leprosy patients suffering from erythema nodosum leprosum are frequently treated with glucocorticosteroids. The role glucocorticosteroids and interferon-gamma (IFN-gamma) play in regulating the interaction of phagocytic cells with Mycobacterium leprae was examined. Monocytes from leprosy patients receiving prednisone therapy responded to lower concentrations of IFN-gamma in vitro with enhanced superoxide anion release when challenged with M. leprae or M. bovis BCG than did monocytes from healthy subjects and other leprosy patients. Although the number of patients was small and the population heterogeneous, the data suggested that prednisone could alter IFN-gamma efficacy and led to the examination of the effect of glucocorticosteroids on IFN-gamma activation of monocytes. IFN-gamma treatment following in vitro dexamethasone pretreatment of monocytes from healthy subjects resulted in a greater enhancement of superoxide anion generation than that observed with IFN-gamma treatment alone. These findings are important considerations in evaluating patient immune function because IFN-gamma is being used in a number of clinical trials with leprosy patients.</p>
  a0148-916X